Alu-Tab Side Effects
Generic Name: aluminum hydroxide
Note: This document contains side effect information about aluminum hydroxide. Some of the dosage forms listed on this page may not apply to the brand name Alu-Tab.
For the Consumer
Applies to aluminum hydroxide: oral suspension
What are some side effects that I need to call my doctor about right away?
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
- Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
What are some other side effects of this drug?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
- Hard stools (constipation).
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
For Healthcare Professionals
Applies to aluminum hydroxide: compounding gel, compounding powder, oral capsule, oral suspension, oral tablet
Although the majority of aluminum ingested is eliminated by the gastrointestinal tract, absorption of aluminum and increases in serum concentrations have been demonstrated. Accumulation of aluminum and resulting toxicity is confined to patients with renal dysfunction and impaired elimination of aluminum.[Ref]
Sources of aluminum in patients with renal failure have included water used for dialysate solutions, in addition to aluminum hydroxide. Adverse effects of aluminum accumulation in these patients has led to monitoring of water source aluminum content by dialysis units and periodic measurements of serum aluminum in patients undergoing chronic dialysis.
High aluminum concentrations in patients are generally also associated with high daily doses. One study suggested that increases in aluminum concentrations in uremic patients were most significant with daily doses greater than 3 grams of aluminum hydroxide. Age of the patient has also been directly correlated with aluminum concentrations with younger age groups perhaps demonstrating higher concentrations.
Concurrent administration of aluminum hydroxide with citrate containing products has been associated with unusually high serum concentrations of aluminum and, especially in cases of renal failure, severe toxicity. It was speculated that citrate increases the solubility and absorption of aluminum.
Aluminum concentrations during aluminum hydroxide therapy has also been correlated with body iron stores. One study demonstrated a negative correlation between serum aluminum concentrations and serum ferritin levels. It was postulated that high serum ferritin and high transferritin saturation might hamper gut absorption of aluminum.
During long-term use, aluminum has been shown to deposit in bone, joints, and the brain of patients who accumulate aluminum.[Ref]
Gastrointestinal side effects have been reported the most frequently. These have included constipation and impaction. Generally, aluminum hydroxide (the active ingredient contained in Alu-Tab) is combined with another antacid so lower doses may be used to counterbalance the constipating effect.[Ref]
Metabolic side effects have included hypophosphatemia with the use of aluminum hydroxide (the active ingredient contained in Alu-Tab) In patients on long-term aluminum hydroxide therapy, especially in association with poor diets, hypophosphatemia may result in muscle weakness, rhabdomyolysis, hemolysis, and encephalopathy.[Ref]
Aluminum hydroxide complexes with phosphate in the gut to form insoluble aluminum phosphate, thus inhibiting the absorption of dietary phosphate. Aluminum hydroxide is commonly used in patients with renal dysfunction to regulate the accumulation of phosphate due to decreased elimination.
Hypophosphatemia is thought to stimulate the conversion of calcifediol (25-hydroxy vitamin D3) to calcitriol (1,25-dihydroxy vitamin D3), a potent stimulator of calcium and phosphorous intestinal absorption and osteoclastic resorption. Hypercalciuria is generally associated with hypophosphatemia.[Ref]
Musculoskeletal adverse effects due to aluminum hydroxide (the active ingredient contained in Alu-Tab) commonly includes osteomalacia, which may occur by two different mechanisms. Osteomalacia may occur due to hypophosphatemia or due to aluminum accumulation in bone. Osteomalacia due to hypophosphatemia is often accompanied by malaise, bone pain, muscular weakness, and bone fractures. Osteomalacia due to aluminum deposition may present in a similar fashion and occurs predominantly in patients with chronic renal failure. Aluminum deposits are seen on bone biopsy.[Ref]
Aluminum hydroxide associated hypophosphatemia, if severe and chronic, results in decreased bone mineralization and potentially osteomalacia. Hypophosphatemia is also thought to stimulate the conversion of calcifediol (25-hydroxy vitamin D3) to calcitriol (1,25-dihydroxy vitamin D3), a potent stimulator of osteoclastic resorption, thus contributing to osteomalacia. These patients generally require phosphorus replacement therapy. Symptoms of osteomalacia may take several weeks to resolve.
Osteomalacia due to aluminum deposition in bone is generally only seen in patients with chronic renal failure. Bone formation slows in response to aluminum bone deposits. Aluminum may also deposit in joint tissue, resulting in arthropathy and hydrarthrosis.[Ref]
Nervous system side effects have included encephalopathy which has occasionally been reported in patients with renal failure on long-term therapy with aluminum hydroxide (the active ingredient contained in Alu-Tab) When available, basal and/or deferoxamine stimulated aluminum serum levels reveal high concentrations.[Ref]
Encephalopathy associated with aluminum accumulation is generally characterized by speech disorders, dysarthria, dyspraxia, dysphasia, tremor, myoclonus, seizures, coma, and death. EEG of patients with aluminum encephalopathy has shown paroxysmal slowing, and diffuse rhythmical bursts of delta activity.
The interval between commencement of aluminum hydroxide therapy and development of encephalopathy in eight reported cases ranged from three weeks to three months. In two of these patients, aluminum serum concentrations of 871 to 2267 mcg/L were reported. These patients were on concomitant sodium citrate therapy. Most chronic dialysis patients develop aluminum encephalopathy slowly over several years.[Ref]
Renal side effects have rarely included formation of renal calculi, most probably due to hypercalciuria, with the use of aluminum hydroxide (the active ingredient contained in Alu-Tab) [Ref]
Antacids may interfere with drug therapies because of their effect on gastric pH, adsorption or binding to drugs, and changes in urinary pH.[Ref]
1. Ittel TH, Gladziwa U, Muck W, Sieberth HG "Hyperaluminaemia in critically ill patients: role of antacid therapy and impaired renal function." Eur J Clin Invest 21 (1991): 96-102
2. Netter P, Kessler M, Burnel D, Hutin MF, Delones S, Benoit J, Gaucher A "Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds." J Rheumatol 11 (1984): 66-70
3. Kirschbaum BB, Schoolwerth AC "Acute aluminum toxicity associated with oral citrate and aluminum- containing antacids." Am J Med Sci 297 (1989): 9-11
4. Weberg R, Berstad A, Aaseth J, Falch JA "Mineral-metabolic side effects of low-dose antacids." Scand J Gastroenterol 20 (1985): 741-6
5. Main J, Ward MK "Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient." BMJ 304 (1992): 1686
6. Brahm M "Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels." Clin Nephrol 25 (1986): 231-5
7. Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G "Hyperaluminemia in renal failure: the influence of age and citrate intake." Clin Nephrol 31 (1989): 40-4
8. Poisson M, Mashaly R, Lebkiri B "Dialysis encephalopathy: recovery after interruption of aluminium intake." Br Med J 2 (1978): 1610-1
9. Huang JY, Huang CC, Lim PS, Wu MS, Leu ML "Effect of body iron stores on serum aluminum level in hemodialysis patients." Nephron 61 (1992): 158-62
10. Girotti MJ, Ruddan J, Cohanim M "Amphojeloma: antacid impaction in a critically ill patient." Can J Surg 27 (1984): 379-80
11. "Product Information. Amphojel (aluminum hydroxide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
12. Baker LR, Ackrill P, Cattell WR, Stamp TC, Watson L "Iatrogenic osteomalacia and myopathy due to phosphate depletion." Br Med J 3 (1974): 150-2
13. Cooke N, Teitelbaum S, Avioli LV "Antacid-induced osteomalacia and nephrolithiasis." Arch Intern Med 138 (1978): 1007-9
14. Insogna KL, Bordley DR, Caro JF, Lockwood DH "Osteomalacia and weakness from excessive antacid ingestion." JAMA 244 (1980): 2544-6
15. Carmichael KA, Fallon MD, Dalinka M, Kaplan FS, Axel L, Haddad JG "Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid." Am J Med 76 (1984): 1137-43
16. Surks MI, Sievert R "Drugs and thyroid function." N Engl J Med 333 (1995): 1688-94
17. Ludwig GD, Kyle CG, de Blanco M ""Tertiary" hyperparathyroidism induced by osteomalacia resulting from phosphorus depletion." Am J Med 43 (1967): 136-40
18. Spencer H, Lender M "Adverse effects of aluminum-containing antacids on mineral metabolism." Gastroenterology 76 (1979): 603-6
19. Sherrard DJ, Ott SM, Andress DL "Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure." Am J Med 79 (1985): 127-30
20. Heaf JG, Podenphant J, Joffe P, Andersen JR, Fugleberg S, Braendstrup O "The effect of oral aluminium salts on the bone of non-dialysed uremic patients." Scand J Urol Nephrol 21 (1987): 229-33
21. Kingswood C, Banks RA, Bunker T, Harrison P, Mackenzie C "Fracture osteomalacia." Lancet 1 (1983): 70-1
22. Alfrey AC, LeGendre GR, Kaehny WD "The dialysis encephalopathy syndrome. Possible aluminum intoxication." N Engl J Med 294 (1976): 184-8
23. Pillion G, Loirat C, Blum C, Poisson M, Bacri JL, Broyer M, Mathieu H "Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure." Int J Pediatr Nephrol 2 (1981): 29-32
24. Sideman S, Manor D "The dialysis dementia syndrome and aluminum intoxication." Nephron 31 (1982): 1-10
25. Masselot JP, Adhemar JP, Jaudon MC, Kleinknecht D, Galli A "Reversible dialysis encephalopathy: role for aluminium-containing gels." Lancet 2 (1978): 1386-7
Some side effects of Alu-Tab may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
More about Alu-Tab (aluminum hydroxide)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews – Add your own review/rating
- Drug class: antacids
Other brands: Alternagel
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.